Search Results - "Erasun Lecuona, C."

Clinical impact of 18F-FDG-PET/CT (PET) in patients (P) with oligometastatic disease (OMD) at a skin and gastrointestinal tumour section by Garcia-Mosquera, J J, Layos Romero, L, Buges, C, España Fernandez, S, Chen, S, Velarde, J M, Felip, E, Erasun Lecuona, C, Angelats, L, Cucurull Salamero, M, Manzano, J L

Get full text

937P Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment by Jové, M., Braña, I., Oliva Bernal, M., Hernando Calvo, A., Erasun Lecuona, C., Assaf Pastrana, J.D., Mato-Berciano, A., Maliandi, M.V., Torres-Manjon, S., Moreno, R., Le, C., Nuciforo, P.G., Alemany, R., Capella, G., Blasco, C., Cascallo Piqueras, M., Mesia Nin, R.

Get full text

1231P Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) by Jove, M., Brana, I., Oliva Bernal, M., Hernando-Calvo, A., Erasun Lecuona, C., Assaf Pastrana, J.D., Bazan Peregrino, M., Mato-Berciano, A., Maliandi, M.V., Torres-Manjon, S., Martinez de Villareal, J., Real, F.X., Nuciforo, P.G., Alemany, R., Capella, G., Blasi, E., Blasco, C., Cascallo Piqueras, M., Mesia Nin, R.

Get full text

Second primary malignancies in patients with breast cancer by Lecuona, C Erasun, Hardy-Werbin, M., Falgas, E Felip, Mosquera, J J García, Salamero, M Cucurull, Te García, I ruel, Vila, M Margeli

Get full text

285PSecond primary malignancies in patients with breast cancer by Lecuona, C Erasun, Hardy-Werbin, M, Falgas, E Felip, Mosquera, J J García, Salamero, M Cucurull, García, I Teruel, Vila, M Margeli

“…Abstract Background The risk of developing second primary malignancies (SPM) in patients (p) with breast cancer (BC) is higher than among the general…”
Get full text

285P - Second primary malignancies in patients with breast cancer by Lecuona, C Erasun, Hardy-Werbin, M., Falgas, E Felip, Mosquera, J J García, Salamero, M Cucurull, Te García, I ruel, Vila, M Margeli

“…The risk of developing second primary malignancies (SPM) in patients (p) with breast cancer (BC) is higher than among the general population. Tamoxifen,…”
Get full text

515PClinical impact of 18F-FDG-PET/CT (PET) in patients (P) with oligometastatic disease (OMD) at a skin and gastrointestinal tumour section by Garcia-Mosquera, J J, Layos Romero, L, Buges, C, España Fernandez, S, Chen, S, Velarde, J M, Felip, E, Erasun Lecuona, C, Angelats, L, Cucurull Salamero, M, Manzano, J L

Get full text

The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC) by Salamero, M Cucurull, Te García, I ruel, Arroyo, A.J., Pardo, B., Gil, M., Piulats, J.M., Pla, H., Fina, C., Ginesta, M P Barretina, Angelats, L., Falgas, E Felip, Lecuona, C Erasun, Mosquera, J J García, Román, S Martinez, Carballas, E., Hernandez, J., Esteve, A., Romeo, M.

Get full text

1021PThe prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC) by Salamero, M Cucurull, García, I Teruel, Arroyo, A J, Pardo, B, Gil, M, Piulats, J M, Pla, H, Fina, C, Ginesta, M P Barretina, Angelats, L, Falgas, E Felip, Lecuona, C Erasun, Mosquera, J J García, Román, S Martinez, Carballas, E, Hernandez, J, Esteve, A, Romeo, M

“…Abstract Background Among the inflammation-related biomarkers, high MLR values are associated to poorer outcomes in different cancers. We explored the…”
Get full text

1021P - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC) by Salamero, M Cucurull, Te García, I ruel, Arroyo, A.J., Pardo, B., Gil, M., Piulats, J.M., Pla, H., Fina, C., Ginesta, M P Barretina, Angelats, L., Falgas, E Felip, Lecuona, C Erasun, Mosquera, J J García, Román, S Martinez, Carballas, E., Hernandez, J., Esteve, A., Romeo, M.

“…Among the inflammation-related biomarkers, high MLR values are associated to poorer outcomes in different cancers. We explored the prognostic role of MLR in a…”
Get full text

KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution by Erasun Lecuona, C., Moran Bueno, M.T., Vila, L., Teruel, I., Angelats, L., Ferrando, A., Plaja, A., Torres, P., Lopez, E., Muriel, R., Muñoz-Marmol, A.M., Mate, J.L., Velarde, J.M., Carcereny Costa, E.

Get full text

KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution by Erasun Lecuona, C., Moran Bueno, M.T., Vila, L., Teruel, I., Angelats, L., Ferrando, A., Plaja, A., Torres, P., Lopez, E., Muriel, R., Muñoz-Marmol, A.M., Mate, J.L., Velarde, J.M., Carcereny Costa, E.

Get full text